Analysts Expect NxStage Medical, Inc. (NXTM) Will Post Quarterly Sales of $108.07 Million
Analysts forecast that NxStage Medical, Inc. (NASDAQ:NXTM) will report sales of $108.07 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for NxStage Medical’s earnings. The highest sales estimate is $109.84 million and the lowest is $106.30 million. NxStage Medical reported sales of $97.30 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 11.1%. The business is scheduled to report its next earnings report on Wednesday, November 14th.
On average, analysts expect that NxStage Medical will report full-year sales of $432.81 million for the current year, with estimates ranging from $429.70 million to $435.91 million. For the next financial year, analysts anticipate that the firm will report sales of $467.80 million, with estimates ranging from $467.30 million to $468.30 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for NxStage Medical.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $106.97 million for the quarter, compared to the consensus estimate of $105.35 million. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%.
Shares of NASDAQ:NXTM traded down $0.05 during mid-day trading on Monday, reaching $28.98. The stock had a trading volume of 314,702 shares, compared to its average volume of 654,908. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -131.73 and a beta of -0.05. NxStage Medical has a twelve month low of $22.70 and a twelve month high of $29.19.
Several large investors have recently made changes to their positions in NXTM. Guggenheim Capital LLC raised its position in shares of NxStage Medical by 106.2% in the 1st quarter. Guggenheim Capital LLC now owns 23,190 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 11,943 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in NxStage Medical during the 1st quarter worth approximately $303,000. Tokio Marine Asset Management Co. Ltd. acquired a new stake in NxStage Medical during the 2nd quarter worth approximately $1,038,000. Steward Partners Investment Advisory LLC raised its holdings in NxStage Medical by 714.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock worth $159,000 after buying an additional 5,000 shares during the period. Finally, Commonwealth Equity Services LLC acquired a new stake in NxStage Medical during the 2nd quarter worth approximately $373,000. Institutional investors and hedge funds own 83.15% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
See Also: What is the S&P 500 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.